Eli Lilly threatens Zepbound copycat makers

Digest more
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Mounjaro,
Eli Lilly Threatens Obesity Drug Copycat Makers After Shortage
Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with plans Tuesday to file two lawsuits and send about fifty cease-and-desist letters.
Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with

Eli Lilly, Hims and weight loss

Digest more
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Key Takeaways Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.The treatments will each cost $1,
Eli Lilly weight loss therapy added to Hims & Hers platform (update)
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.
Eli Lilly's Weight-Loss Drug Mounjaro Gets Thumbs Up From JM Financial — Here's Why
JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large addressable market.
Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Live Mint on MSN12d
Mounjaro hits shelves in India: How Eli Lilly’s weight loss drug compares with Ozempic — price, side effects and more
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...
CNBCTV186d
Exclusive | Eli Lilly's Global CEO David Ricks says might make Mounjaro in India
GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...
Explore more
Eli Lilly and Company (LLY): Among Billionaire Ken Fisher’s Top Growth Stock Picks
We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...